Reading Time: 3 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond
Author: Eleanor Green
I work in the Research Development team at the MND Association as a Senior Research Co-ordinator. I completed my undergraduate degree in Biomedical Science and I became very interested in neuroscience throughout my degree. Following on from this, I did a Master’s degree in Molecular Medicine, with a focus on gene therapies. As part of my role, I identify interesting updates in MND research and communicate these via the blog in an understandable and engaging way.
Reading Time: 5 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 5 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 3 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type correspond
Reading Time: 7 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 6 minutesThis blog is part of our Symposium Blogathon series – where we are counting down to the 33rd International Symposium. Numbers in bold blue type
Reading Time: 2 minutesIt’s that time of year again where the research team at the Association are counting down to the start of the largest scientific and medical
Reading Time: 6 minutesOn Tuesday 4 October 2022, a new paper was published which investigated the risk of developing a neurodegenerative disease, such as MND, among former Scottish
Reading Time: 6 minutesOn 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States.
Reading Time: 6 minutesThe recent publication of the results from the Phase 3 Tofersen trial, an experimental gene therapy for the treatment of MND in people with a